Abstract
The University of Central Florida invention is a disease-modifying drug therapy for osteoarthritis. Compounds from a natural product library were screened for stimulation of type II collagen expression in an in vitro reporter assay. Hit compounds have been identified and in silico analysis suggests that they are targeting the dopamine receptor D4.
Partnering Opportunity
The research team is seeking partners for licensing and/or research collaboration.
Stage of Development
Prototype available.
Benefit
Stimulates type II collagen expression in adult chondrocytesPromotes anabolism versus catabolism Dopamine receptor D4, sigma opioid receptor, and cholinergic receptor targeting therapies are novel targets for treating osteoarthritisMarket Application
Tissue engineering for research and implantation into the osteoarthritic jointStimulation of regeneration in an osteoarthritic jointPrevention of osteoarthritis after joint trauma
Brochure
